Swiss pharmaceutical company Novartis has dismissed criticism that it allegedly withheld information about animal testing data inaccuracies to United States authorities for a human gene therapy.
This content was published on
1 minute
swissinfo.ch/ug
NovartisExternal link said its subsidiary in California began investigating the alleged data manipulation for its gene therapy Zolgensma as soon as it learned about it. Once the company had interim conclusions, it shared the informationExternal link with the US Food and Drug Administration (FDA).
The agency said Novartis did not disclose the information about suspected data manipulation until after the $2.1 million (CHF2.1) therapy treatment for children under the age of two won approval by the US regulator in May.
In a statement, the pharma company explained that the data in question were a small portion of its overall submission and limited to an older process no longer in use.
“The assays in question were used for initial product testing and are nor currently used for commercial product release,” Novartis said.
According to the company, Zolgensma, the most expensive treatment ever, is safe, of high quality and effective in treating patients with spinal muscular atrophy.
The FDA has indicated that the drug will remain on the market. The company’s actions are being assessed and could lead to criminal or civil penalties if appropriate.
More
More
How can a drug cost $2.1 million?
This content was published on
US authorities have approved a $2.1 million gene therapy, making it the most expensive drug ever. Can such a price tag be justified?
Train vs plane: would you take a direct train between London and Geneva?
Eurostar is planning to run direct trains from Britain to Germany and Switzerland from the early 2030s. Would you favour the train over the plane? If not, why not?
Legal action filed against Swiss purchase of Israeli drones
This content was published on
Legal action aims to put an end to the delivery of the six Elbit reconnaissance drones already plagued by delays and setbacks.
Higher direct payments fail to curb scrub encroachment on alpine pastures
This content was published on
The scrub encroachment on Swiss alpine pastures leads to the loss of grassland and damages the typical landscape. It is also responsible for the decline in biodiversity. Despite higher direct payments, the bushes continue to spread.
Head of Swiss financial regulator’s Banks division quits
This content was published on
Thomas Hirschi, head of the Banks division of the Swiss Financial Market Supervisory Authority FINMA will leave at the end of August.
Swiss population satisfied with life according to survey
This content was published on
In a survey, the population of German-speaking and French-speaking Switzerland expressed general satisfaction with their lives. Respondents were less happy with politics and their personal finances, according to the online comparison service Moneyland.
WHO ‘extremely concerned’ about growing vaccination scepticism
This content was published on
According to the World Health Organisation (WHO), vaccination scepticism and a collapse in funding for vaccination campaigns pose a major threat to the health of the world's population.
High-net-worth individuals prioritise well-being over material possessions
This content was published on
The priorities of wealthy private individuals have shifted against the backdrop of ongoing geopolitical tensions and trade disputes. While spending on luxury goods is declining, demand for travel and experiences is unabated.
Swiss researchers sequence genome of 1918 Spanish flu virus
This content was published on
Researchers from the Universities of Basel and Zurich (UZH) have sequenced the genome of the Spanish flu virus, thanks to a sample taken from an 18-year-old Swiss boy who died in the city on the Limmat in 1918, when the pandemic spread around the world.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Pharma company Sandoz named in US price-fixing lawsuit
This content was published on
The Germany-based subsidiary of Novartis is targeted in a 44-state class action suit for breaching rules on fair competition.
This content was published on
Swiss pharmaceutical Novartis must face a US government lawsuit accusing it of paying millions of dollars in kickbacks to doctors.
This content was published on
Pressure groups Public Eye and Médecins du Monde have filed their objection to the European patent office in Munich. They claim that Kymriah was not invented by Novartis because the research behind the drug was carried out by public institutions. The medicament, which is used to treat leukaemia and lymph gland cancer on patients who have…
Novartis faces questions about proxy voting independence
This content was published on
Proxy votes submitted by shareholders ended up at Novartis headquarters instead of the elected representative ahead of the annual general meeting.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.